Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple antihypertensive therapy for mild to moderate aortic stenosis
ACTRN12621001732875Phase 3Recruiting
- Sponsor
- University of Otago
- Start
- Sep 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bisoprolol, candesartan and amlodipine in aortic stenosis (AS) and hypertension (HTN) (2 arms), sponsored by University of Otago. Primary endpoint: Composite of aortic valve replacement, hospitalization with heart failure or aortic stenosis, or cardiovascular death. Started Sep 2022; status: recruiting.
02
Drugs
bisoprololcandesartanamlodipine
03
Conditions
aortic stenosis (AS)hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12621001732875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001732875.